logo
  

Takeda: Phase 3 PhALLCON Trial Meets Primary Endpoint

Takeda (TAK) announced that the phase 3 PhALLCON trial met its primary endpoint, showing that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated with ICLUSIG plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease-negative complete remission compared to imatinib. In the trial, no new safety signals were observed. The PhALLCON study is a phase 3 randomized, international, open-label multicenter trial.

Takeda said the data from this trial will be discussed with regulatory agencies and shared with the scientific community in the future.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Follow RTT